Should you buy IQVIA stock now?
Yes, the technical signal for IQVIA is currently BUY. IQVIA trades at $229.76 as of 8/6/2026. The overall technical signal is: Strong Buy. The technical analysis shows the following: MACD is positive (bullish trend) at 11.257 with rising momentum (signal: 10.104); RSI is at 65.7 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $275.17 points to 19.8% upside. The stock is in a broader uptrend (above SMA50/SMA200). This is a technical observation based on current data, not investment advice.
What is the price target for IQVIA stock?
The average analyst price target for IQVIA is $275.17. The current price is $229.76, which gives an upside of 19.8%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $247.65 and $302.69.
Is IQVIA a dividend stock?
No, IQVIA does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of IQVIA stock?
IQVIA is rated as a stock with moderate risk. the annual standard deviation is 41.3%, which classifies the stock as moderate risk.
Is IQVIA overvalued?
No, IQVIA is considered undervalued based on the analyst price target (19.8% upside). IQVIA has the following valuation ratios: a P/E ratio of 29.0 (moderately to highly valued), a P/S ratio of 2.2, a P/B ratio of 6.3. The analyst price target suggests that the stock is undervalued by 19.8%.
Is IQVIA overbought?
No, IQVIA is not overbought. RSI is at 65.7 (neutral zone). The technical indicators show: RSI is at 65.7 (upper neutral zone), which shows positive momentum but is not yet overbought. In addition, the price is 5.7% above the 20-day average (short-term uptrend). In addition, MACD is positive with rising momentum (bullish).
When is the next IQVIA earnings report?
The date of the next earnings report for IQVIA has not been published yet. Check the company's investor calendar for updates.
Is IQVIA shorted?
Yes, IQVIA is shorted with 3.7% of the free float sold short. This is a moderate level of short selling, within the normal range for most stocks. Data is updated daily based on official filings with the SEC.
Are insiders buying IQVIA stock?
No, insiders are not buying IQVIA shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 5 sales. On a net basis, 41,681,675 $ worth of shares were sold. Across the last 20 reported transactions, the split is 0 purchases and 20 sales, with a net 75,035,843 $ sold. Active sellers include STAUB W RICHARD, Patel Bhavik, Sherbet Eric and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is IQVIA a good stock?
Based on our total score, IQVIA is rated as a good stock with a total score of 65 out of 100. The stock scores above average on value, quality and momentum – it is among the top 35% in our database. The score is made up of Value: 45/100, Quality: 62/100, Momentum: 89/100. In addition: analysts see 19.8% upside to the price target; technical signal: Strong Buy. Whether IQVIA is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for IQVIA stock?
The outlook for IQVIA based on current data: the average analyst price target is $275.17 (+19.8%); the stock is in an uptrend (above SMA50 and SMA200); the P/E ratio is 29.0 (moderate). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is IQVIA stock rising?
IQVIA is rising right now. The technical indicators show: the price is 5.7% above the 20-day average; MACD is positive with rising momentum (bullish signal); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can IQVIA go?
The average analyst price target for IQVIA is $275.17, which corresponds to a potential gain of 19.8% from the current price of $229.76. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can IQVIA fall?
We lack enough history to give a specific floor for IQVIA. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does IQVIA do?
IQVIA Holdings Inc. laver avancerede analyser og teknologi til medicinalindustrien verden over. De tjener primært penge på tre områder: teknologi- og analyseløsninger, forskning og udvikling, samt salg og medicinske løsninger.
IQVIA er især kendt for deres cloud-baserede appl... The company belongs to the Sundhed sector, more specifically the Diagnostics & Research industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate IQVIA as an investment.
Did IQVIA raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from IQVIA. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is IQVIA making money or losing money?
Yes, IQVIA is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 8.1% — which is moderate. The operating margin (profit before interest and taxes) is 13.0%. At a P/E ratio of 29.0, you currently pay 29.0 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can IQVIA go bankrupt?
The bankruptcy risk of IQVIA is rated as elevated. Altman Z2 (a model for assessing financial distress) is 1.10 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 7 — which is strong. Debt relative to equity is 343% (high). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does IQVIA have a lot of debt?
Yes, IQVIA has elevated debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 343%. For the sundhed sector, anything above 150% counts as elevated — that raises the financial risk, especially if interest rates rise or earnings fall. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector. Can IQVIA service its debt? Can service its debt, but it weighs on the company — the interest coverage ratio (how many times earnings can cover interest payments) is 2.5x, and net debt equals 4.7 years of earnings (EBITDA).
